Table 1.
Targets of PARP * inhibitors used in this study.
| PARP Inhibitors | PARP1 | PARP2 | PARP3 | PARP5a/TNKS1 ^ | PARP5b/TNKS2 § |
|---|---|---|---|---|---|
| A-966492 [27] | ++++ | +++ | |||
| AG-14361 [27] | ++ | ||||
| AZD2461 [27] | ++ | +++ | + | + | |
| E7449 [27] | ++++ | ++++ | |||
| G007-LK [27] | + | + | |||
| Niraparib [27] | +++ | +++ | |||
| NMS-P118 [27] | ++ | ||||
| NU1025 [28] | + | ||||
| Olaparib [27] | ++ | ++++ | |||
| PJ34-HCl [29] | ++ | ++ | |||
| Rucaparib [30] | +++ | +++ | +++ | ||
| Talazoparib [27] | ++++ | ||||
| UPF-1069 [27] | + | ++ |
* Poly (ADP-ribose) polymerase; ^ Tankyrase 1; § Tankyrase 2. There are 18 members of the PARP family [31]. PARP1, PARP2, PARP5a/TNKS1, and PARP5b/TNKS2 are poly-ADP-ribosyl transferases, while PARP3 is a mono-ADP-ribosyl transferase [32]. These PARPs are involved in PARP enzymatic activity [31,33]. “+” indicates an inhibitory effect. A higher “+” designation marks increased inhibition.